are the most frequent intracranial brain tumour. Significant progress has been
made in the molecular understanding of meningioma (1). However, no progress has been made in
regards to finding drug treatments for meningiomas.
We have performed
a systematic proteomic screen of meningiomas of different grades (2) and genotypes (Akther in preparation).
Although upregulated and downregulated differentially expressed proteins were
identified, subsequent bioinformatics analyses including pathway analysis and
functional analysis focused on upregulated proteins (2).
a more complete understanding of proteins relevant in meningioma development
and progression a systematic analysis and validation of downregulated proteins
and signalling pathways from existing datasets is needed. In particular, the
role of tumour suppressor genes in contributing to meningioma progression has
not been fully elucidated, this includes phosphatases which are frequently
downregulated in tumours. Larger
scale RNA expression studies showed examples of downregulation (3, 4) associated with meningioma progression.
Comparing the RNA expression data from with our proteomic data we found a
number of concordantly downregulated RNA’s and protein (5).
In addition to bioinformatics analysis of
existing large datasets the PhD project will include validation of differentially
regulated proteins’ with targeted proteomics and functional analysis in
established in vitro disease models.
supervisory team is part of our large Brain Tumour centre and brings together
expertise in brain tumour pathology, basic mechanisms of tumourigenesis and
translation. This project will not use animals or animal derived cells or
tissues. Training will be provided for the development of both knowledge and
technical skills to enable the trainee to conduct high-quality and independent
1. Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO,
Horbinski CM, et al. Molecular and translational advances in meningiomas.
2. Dunn J, Ferluga S, Sharma V,
Futschik M, Hilton DA, Adams CL, et al. Proteomic analysis discovers the
differential expression of novel proteins and phosphoproteins in meningioma
including NEK9, HK2 and SET and deregulation of RNA metabolism. EBioMedicine.
M, Mock A, Jungk C, Sahm F, Ull AT, Warta R, et al. Transcriptomic analysis of
aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers
independent of WHO grade. Oncotarget. 2016;7(12):14551-68.
AN, Zhang B, Martinez-Lage M, Xiang C, Tosi U, Thawani JP, et al. Transcriptome
signatures associated with meningioma progression. Acta neuropathologica
J, Lenis VP, Hilton DA, Warta R, Herold-Mende C, Hanemann CO, et al.
Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma.